Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies

Trial Profile

Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Dec 2016

At a glance

  • Drugs Abiraterone acetate (Primary) ; Dasatinib (Primary) ; Sunitinib (Primary) ; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
    • 21 Sep 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
    • 21 Sep 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top